THE
FUTURE
OF MEDICINE
NOW
OUR
SCIENCE
Coeptis’ science is built on the notion that cell therapies should be safe, effective, and available for everyone. Recent medical breakthroughs in cell therapy are quickly leading to a renaissance in the treatment of diseases once believed to be untreatable. Coeptis is developing a proprietary, allogeneic cell generation platform and a pipeline of innovative cell therapies which we believe may universalize the treatment of many debilitating diseases.
OUR
SCIENTIFIC COLLABORATIONS
- Coeptis is working with researchers from the University of Pittsburgh and other scientific and medical collaborators to continue developing SNAP-CAR cell therapy with the goal to pursue clinical trials. Coeptis has licensed the worldwide development and commercialization rights to the SNAP-CAR technology in the field of human cancer and autoimmune diseases.
- VyGen-Bio is a discovery-stage, cell-based immunotherapy company focused on the development of transformational technology platforms: GEAR-NK, modified natural killer cell-based therapeutics (NK cells), optimized to be co-administered with targeted antibodies; and, CD38 In Vitro Diagnostic, a companion diagnostic being developed to select patient populations most likely to benefit from targeted antibody therapies.
- Headquartered in Tampa, Florida on the campus of the H. Lee Moffitt Cancer Center, VyGen-Bio is a majority-owned subsidiary of Vycellix, Inc. VyGen-Bio is a member-partner in “NextGenNK”, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI and funded by Sweden’s innovations agency, Vinnova. KI is globally recognized for its Nobel Assembly, which awards the Nobel Prize in Physiology or Medicine.
OTHER DEVELOPMENT AND CLINICAL COLLABORATORS
